-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On Summit Therapeutics with Buy Rating, Announces Price Target of $45

Benzinga·04/08/2026 10:21:16
Listen to the news
Stifel analyst Dara Azar initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and announces Price Target of $45.